Chromosomal Microarray Analysis (CMA)

Smiling doctor holding baby

Chromosomal Microarray Analysis (CMA) has the highest diagnostic yield of any single clinically available test for children with global developmental delay, intellectual disability, autism spectrum disorders, and multiple congenital anomalies and has been recommended by the American College of Medical Genetics (ACMG) and the American Academy of Neurology (AAN) as a first-line genetic test for individuals with these conditions. CMA can quickly provide a specific genetic diagnosis that can avoid extensive testing including: blood and urine tests, EEG, MRIs, lumbar punctures, and skin and muscle biopsies. Widespread coverage policy adoption by major insurance providers over the past year help make CMA a routine part of clinical practice.

AAN Template Coverage Policy on CMA for Intellectual Disabilities

Add ClariSure to Your Practice
If you are already a valued client of Quest Diagnostics, contact your local representative or call (866) MY-QUEST to ask about how to order ClariSure or fill out our form to speak to a highly trained neurology account executive in your area.